TNG:EPA
Transgene SA
€0.75
arrow_downward
-0.79%(-0.0060) 1D
Nov 11, 11:06:09 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€0.75
High
€0.75
Low
€0.75
Mkt. cap
207.80M
Avg. vol.
89.43K
Volume
6.84K
52-wk high
€1.36
52-wk low
€0.67
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
Open
€0.75
High
€0.75
Low
€0.75
Mkt. cap
207.80M
Avg. vol.
89.43K
Volume
6.84K
52-wk high
€1.36
52-wk low
€0.67
EPS
-€0.17
Shares outstanding
278.56M
No. of employees
152
News stories
From web sources and news partners
Idéal Investisseur
·
1 day ago
Transgene: €84.3 million in cash, financial visibility until early 2028
The Manila Times
·
1 day ago
Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA
CEO-
Employees152
FoundedDec 1979
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitetransgene.com